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Improving short-term results with intestine transplan-
tation have allowed more patients to benefit with
nearly 700 patients alive in the United States with a
functioning allograft at the end of 2007. This success
has led to an increase in demand. Time to transplant
and waiting list mortality have significantly improved
over the decade, but mortality remains high, espe-
cially for infants and adults with concomitant liver fail-
ure. The approximately 200 intestines recovered an-
nually from deceased donors represent less than 3%
of donors who have at least one organ recovered.
Consent practice varies widely by OPTN region.
Opportunities for improving intestine recovery and
utilization include improving consent rates and stan-
dardizing donor selection criteria. One-year patient and
intestine graft survival is 89% and 79% for intestine-
only recipients and 72% and 69% for liver-intestine re-
cipients, respectively. By 10 years, patient and intestine
survival falls to 46% and 29% for intestine-only recipi-
ents, and 42% and 39% for liver-intestine, respectively.
Immunosuppression practice employs peri-operative
antibody induction therapy in 60% of cases; acute re-
jection is reported in 30%–40% of recipients at one year.
Data on long-term nutritional outcomes and morbidi-
ties are limited, while the cause and therapy for late
graft loss from chronic rejection are areas of ongoing
investigation.
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Introduction
As experience has increased with intestine transplantation,
areas for improvement have become more apparent and
include the need to reduce waiting list mortality, as well as
optimize long-term outcomes. While the Organ Procure-
ment and Transplantation Network (OPTN)/Scientific Reg-
istry of Transplant Recipients (SRTR) Annual Report has
heretofore reviewed the status of both liver and intestine
transplants in the same manuscript, the present article
specifically evaluates intestine transplantation as a discrete
field, defining issues for both isolated intestine transplan-
tation as well as intestine transplantation performed with
other organs. This article analyzes the trends in intestine
donation and transplantation over the last decade using
data from the 2009 OPTN/SRTR Annual Report; it also pro-
vides additional analysis on donor characteristics and long-
term outcomes conducted specifically for this manuscript.
The areas of focus in this article mirror the primary ar-
eas where improvement can occur within this growing
transplant field, with a hope to foster better understand-
ing of both the donor and recipient populations, analysis
of waiting list outcomes, changes in allocation policy, anal-
ysis of pertinent immunosuppression practices and a re-
view of the short- and long-term outcomes after intestine
transplantation.
Nomenclature
Intestinal transplantation remains a challenging effort for
patients and clinicians. Central to moving the field for-
ward is the ability to compare similar operations across
centers so progress can be achieved. A critical limitation
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in this regard is the lack of a consistent system of
nomenclature for the various types of transplant proce-
dures. Commonly used terms include isolated small bowel,
multivisceral, liver-small bowel and combined liver-small
bowel-pancreas transplantation. Often, these abdominal
transplants are combined with evisceration of portions of
the entire foregut including the spleen. All these variables
can have an impact on patient outcomes. As a conse-
quence, consistent nomenclature is essential so similar
transplant procedures can be compared, critical analyses
performed and efforts initiated to improve outcomes.
In 2007, experts from major intestine transplant programs
around the world met at the International Small Bowel
Transplant Symposium with the intent of creating a consis-
tent and accurate nomenclature. The consensus reached
at this meeting was that the term multivisceral transplan-
tation meant different things to different programs and as
a consequence, the term should be abandoned. A more
descriptive system was proposed. In particular, it was
strongly urged that the type of intestine transplant per-
formed be broadly based on two categories: with or with-
out simultaneous liver transplant. The first category would
represent the typical combined liver, small bowel and pan-
creas transplant. This is the most commonly performed
form of intestinal transplant when it is combined with a
liver. Modifiers to this operation would then reflect whether
the transplant was performed with or without evisceration
of the recipient foregut. This would provide greater consis-
tency in identifying the various types of transplants and, in
particular, allow appropriate comparisons to be performed.
The term isolated small bowel transplantation is accurate
in its description, so no changes were proposed to it. In-
testine transplants may also include the stomach and the
colon, which are not organs that are allocated alone in the
United States. In this article, we do not report data on
the inclusion of the stomach and colon. For selected anal-
yses, we do separately report on isolated intestine trans-
plants and on intestine transplants that included the liver
(and possibly pancreas and/or kidney).
Candidate and Recipient Demographics
Candidates on the waiting list for intestine transplantation
have increased from 101 (71 active and 30 inactive) at the
end of 1999 to 212 in 2008 (146 active and 66 inactive)
[Table 10.1a,b]. The number of inactive registrations may
reflect a clinical period of observation to assess potential
for intestinal adaptation. Similarly, new registrations have
increased from 149 in 1999 to 267 in 2008, with over 50%
of the active patients being 5 years of age or younger
[Table 10.2]. Although there is some variation from year to
year, the racial/ethnic composition of the intestine trans-
plant list at the end of 2008 was 65% white, 18% African
American, 16% Hispanic, 1% Asian and 0.5% other or
multiple races [Table 10.1a,b]. This is similar to the U.S.
population in 2008, although there are fewer Asians on
the intestine waiting list than in the U.S. general popula-
tion (1). The racial composition of the active (64% white)
and inactive candidates (63% white) is similar. Over the
decade, male candidates made up approximately 60% of
the active waiting list, ranging from 53% in 2000 to 65%
in 1999. The blood types of active candidates on the intes-
tine waiting list are also in approximate proportion to those
observed in the general population (for 2008: A = 31%,
AB = 5%, B = 14% and O = 50%). U.S. residents ac-
counted for over 94% of the listed candidates from 1999
through 2008 (range 94.1%–99.5%).
In the United States, there is no separate waiting list for
candidates that are waiting for an intestine and additional
organs, such as a liver. To identify these individuals, we
matched the candidates on the intestine waiting list to the
liver, pancreas and kidney waiting lists at the center where
they were listed for an intestine (the thoracic organ lists
were also checked and no intestine candidate was simul-
taneously listed for heart or lung between 1999 and 2008).
If the candidate was ever on the list for another organ while
they were listed for intestine, we classified them as wait-
ing for either an intestine and liver (and possibly pancreas
or kidney) or an intestine without a liver but with other or-
gans. If the candidate never appeared on the waiting list
for another organ at their center, he or she was considered
to be waiting for an isolated intestine graft (also referred to
here as intestine alone or intestine only). If an intestine can-
didate was listed at more than one transplant center, each
registration was considered separately as listing behavior
could be different at each center.
Over the decade, the proportions of patients waiting for
either an intestine alone or an intestine with organs other
than the liver has grown from 27% and 1% in 1999 to
40% and 7% in 2008, respectively. The fraction waiting
for an intestine with a liver has decreased from 72% in
1999 to 54% in 2008. There has been a gradual increase
in the proportion of candidates listed for isolated intestine
transplant, possibly due to earlier listing (prior to the need
for liver transplantation), reflecting the recognition that iso-
lated intestine transplant may be effective if liver disease
is present but has not progressed too far for recovery to
occur (Figure 1A and B). The initial listing status for iso-
lated intestine was Status 2 for most candidates but varied
over time from 74% in 1999 to a low of 42% in 2002 and
was 62% in 2008. In contrast, candidates listed for both
liver and intestine were usually listed at Status 1, from a
low of 55% in 1999 to a high of 80% in 2003 and 73%
in 2008. Note that not all of these candidates were listed
for liver when they were added to the intestine list; many
were added to the liver list at some time after intestine list-
ing. The number and proportion of children being listed for
intestine without liver appears to be increasing in all age
groups except for the <1 year group. Since children con-
stitute the majority of intestine candidates, the aggregate
trends do not reflect that, in contrast, in the smaller adult
population, the proportion of candidates listed for intestine

































































Source: SRTR analysis, data as of May 2009. Includes IN candidates ever listed for liver while waiting.
Figure 1: (A). Number of candidates on the intestine waiting
list at year-end by age, 1999–2008: intestine only. (B) Number
of candidates on the intestine waiting list at year-end by age,
1999–2008: also listed for liver.
with liver is increasing. Approximately 10% of the patients
active on the intestine list at the end of 2007 were waiting
for a second or third graft, compared to 6% of those active
on the waiting list at the end of 2008 [Table 10.1a].
Transplant recipients
Experience with intestine transplantation has increased
and changed over the past decade but remains concen-
trated at a few large centers. In 1999, there were three
programs that performed more than 10 intestine trans-
plants and eight programs that performed fewer than 10
transplants. Also in 1999, 81% of intestine transplants per-
formed in the United States were in four OPTN regions (2,
3, 8 and 9). In 2008, four regions still accounted for nearly
82% of intestine transplants, but they were regions 2, 3, 8
and 10. In 2008, intestine transplants were equally divided
between pediatric (less than 18 years) and adult recipients
and between males and females [Table 10.4]. Two-thirds
of the transplant recipients were white, 17% African Amer-
ican and 11% Hispanic. The payment source was private
insurance for 37%, Medicaid for 41%, Medicare for 11%
and other sources for 11%. Five percent of recipients were
nonresident aliens. Short gut syndrome accounted for 73%
of cases in 2008, functional bowel problems for 15% of
cases and other causes represented 12% of cases.
Over time, there has been a trend in the community to-
ward either avoiding intestine transplantation in critically
ill, unstable patients or listing candidates earlier in the dis-
ease process prior to hospitalization. This appears to be
reflected in the data. In 1999, almost a third of the re-
cipients were in intensive care at the time of transplan-
tation whereas in 2008, 70% were not hospitalized, 18%
were hospitalized and only 12% were in intensive care
[Table 10.4]. Interestingly, the calculated laboratory Model
for End-Stage Liver Disease (MELD) and Pediatric End-
Stage Liver Disease (PELD) score profiles of patients re-
ceiving livers with the intestine graft have not changed
substantially over time. Looking at the liver waiting list sta-
tus (match MELD and PELD) of those patients who also
received a liver graft with the intestine graft in 2008 shows
that 17% had a liver status of 1B at the time of trans-
plant. Of the remaining patients, almost 80% of the adults
had match MELD scores greater than 20 and almost 80%
of children had match PELD scores greater than 30. The
hospitalization status of the recipient at the time of trans-
plantation remains a strong prognostic factor for patient
survival, with an unadjusted 1-year survival rate of 83% for
recipients not waiting in the hospital, 73% for recipients
waiting in the hospital and only 50% for recipients waiting
in the intensive care unit [Table 10.14].
Waiting List Outcomes
Table 1 lists the outcomes at 1 and 3 years after listing
for intestine transplant. Of note, only 9% of patients died
in 2007 within 1 year of listing compared to nearly 20%
in each of the preceding 3 years. For the first time, there
appears to be an improvement in the percentage of pa-
tients who have died within 1 year of listing. Determining
whether this is a permanent improvement and the factors
leading to this improvement will require ongoing analysis.
In 2007, 18% of listed patients received an isolated intes-
tine transplant and 41% received a multiorgan transplant
within 12 months of listing. Only 3% were removed for
improved condition. Time to transplant (TT) for the entire
intestine waiting list has fallen from a median of 313 days in
1999 to 142 days in 2008 [Table 10.2]. Despite this decline,
the longest waiting times are consistently in the youngest
children. There does not appear to be any difference in
waiting time based on sex or ethnicity.
Median time to transplant is shorter for intestine only can-
didates but TT appears to be decreasing for all candidates
whether they are listed for a liver or not (Figure 2). There
is large variation in TT based on age and geography. For
isolated intestine transplantation, the longest median TT
is for the pediatric patients (under 18 years) at close to 1
year (356 days) in 2008, while adults aged 18 years and
older had a median TT of 27 days in 2008, clearly reflecting
the availability of appropriately size-matched donors. This
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Table 1: Outcomes at 1 and 3 years after listing for candidates on the intestine transplant waiting list (both isolated intestine and
multiorgan), 1999–2007
Year of listing
1999 2000 2001 2002 2003 2004 2005 2006 2007
Total listings during calendar year (N) 132 155 210 195 195 244 275 312 278
Status 1 year after listing (%)
Still on waiting list 22.7 22.6 21.4 16.4 16.9 17.6 18.9 21.2 23.0
Status 1 10.6 12.9 11.4 9.2 10.8 9.8 9.8 11.5 9.7
Not status 1 6.8 5.2 5.7 4.1 3.1 2.9 3.3 4.2 6.5
Inactive 5.3 4.5 4.3 3.1 3.1 4.9 5.8 5.4 6.8
Received transplant 48.5 51.6 51.0 50.3 52.3 56.6 54.2 53.5 59.7
Intestine alone transplant 16.7 20.0 21.9 19.5 21.5 21.3 17.5 17.0 18.3
Multiple organ 31.8 31.6 29.0 30.8 30.8 35.2 36.7 36.5 41.4
Died within one year of listing 22.7 18.1 20.5 24.1 22.1 18.4 17.8 17.0 8.6
Condition worsened/medically unsuitable 3.0 0.6 1.4 1.5 1.5 1.6 5.8 4.5 5.0
No record of subsequent death 1.5 0.0 1.0 1.0 0.5 0.0 2.2 1.9 1.1
Died after removal as too sick 1.5 0.6 0.5 0.5 1.0 1.6 3.6 2.6 4.0
Condition improved 0.0 2.6 1.9 2.6 3.1 3.3 2.2 1.6 2.5
Removed for other reasons 3.0 4.5 3.8 5.1 4.1 2.5 1.1 2.2 1.1
Status 3 years after listing (%)
Still on waiting list 10.6 9.7 4.8 4.6 4.6 7.0 9.1 + +
Status 1 3.0 2.6 0.0 1.0 1.5 2.5 1.8 + +
Not status 1 3.0 3.9 1.0 1.0 1.0 0.8 4.0 + +
Inactive 4.5 3.2 3.8 2.6 2.1 3.7 3.3 + +
Received transplant 56.8 56.1 60.0 54.9 57.4 63.1 58.2 + +
Intestine alone transplant 18.2 21.9 24.8 20.5 23.1 23.8 18.2 + +
Multiple organ 38.6 34.2 35.2 34.4 34.4 39.3 40.0 + +
Died within one year of listing 25.8 22.6 25.7 26.2 25.6 18.9 19.6 + +
Condition worsened/medically unsuitable 3.0 1.3 1.4 2.6 1.5 1.6 6.2 + +
No record of subsequent death 1.5 0.0 1.0 2.1 0.5 0.0 2.5 + +
Died after removal as too sick 1.5 1.3 0.5 0.5 1.0 1.6 3.6 + +
Condition improved 0.0 5.8 3.3 3.6 4.1 4.9 4.0 + +
Removed for other reasons 3.8 4.5 4.8 8.2 6.7 4.5 2.9 + +
Source: SRTR analysis, data as of May 2009.
+ Insufficient follow-up available to present statistics for this year.
pattern was similar, but not so marked, for candidates re-
quiring liver as well as intestine transplants. For <1 year
old infants, the median TT in 2008 was 324 days, falling to
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Source: 2009 OPTN/SRTR Annual Report, Table 10.2 and SRTR Analysis.
Figure 2: Median time to transplant (TT) for new intestine
waiting list registrations, 1999–2008.
shorter for isolated intestine candidates listed initially at
Status 1 versus Status 2 (41 vs. 109 days in 2008). For liver-
intestine candidates, the pattern is different, with those
initially listed as Status 2 on the intestine list (about 25%
of 2008 new liver-intestine listings) having a shorter me-
dian TT (127 days) than those listed as Status 1 (267 days).
In 2008, nearly one-third of Status 1 new liver-intestine
listings were for candidates aged 18 years and older com-
pared to one-quarter of the Status 2 candidates; pediatric
liver candidates are given priority over adults for pediatric
liver donors.
The geographical differences observed are challenging to
explain, but are likely associated with the location of the
larger intestine transplant programs and possibly related
to differences in the age mix at different centers. In 2008,
there were seven programs that performed more than 10
intestine transplants and 10 centers that performed six or
fewer transplants. Region 2, which contains three of the
larger programs, had 37% of all new intestine listings in
2008 and a relatively long median TT at 260 days in 2007.
Region 5, with one large center and two smaller centers,
had the longest median TT at 314 days in 2007.
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Source: 2009 OPTN/SRTR Annual Report, Table 1.6.
Figure 3: Unadjusted death rates per 1000 patient years at
risk for patients on the waiting list by organ, 1999–2008.
Region 2 had 52% of the U.S. candidates waiting for
isolated intestine transplants in 2008. Median time to
transplant for intestine only candidates was 176 days in
2008 in Region 2, down from 264 days in 2007. The re-
maining intestine only listings were spread across seven
regions, with too few candidates per region to calculate
meaningful statistics. Median TT for those waiting for both
a liver and intestine mirrors that for all intestine candidates.
For the years prior to 2008, annual death rates on the in-
testine transplant list per 1000 patient-years at risk were
greater than for any other organ transplant candidate popu-
lation (Figure 3). However, the survival of candidates wait-
ing for intestine transplants also showed the greatest im-
provement among solid organ waiting lists over the last
10 years, falling from 496 deaths per 1000 patient-years at
risk in 1999 to 130 deaths per 1000 patient-years at risk in
2008. In fact, in 2008 the death rate fell below that of heart
and heart-lung candidates for the first time and was the
same as that of lung transplant candidates. The majority
of these deaths were among the patients awaiting trans-
plantation with intestine and an additional organ(s), usually
liver (2,3). Out of the 28 deaths on the intestine waiting
list in 2008, 23 were among candidates waiting for both
an intestine and a liver, three were waiting for an intestine
and another organ but not the liver, while two were wait-
ing for isolated intestine transplants. The waiting list death
rates for candidates listed for isolated intestine transplan-
tation fell from 271 deaths per 1000 patient-years at risk in
1999 to 24 in 2008. Likewise, for combined liver-intestine
listings, death rates fell from 576 in 1999 to 194 by 2008.
Death rates were highest in the youngest children (aged 5
years or younger) but lowest for the pediatric candidates
between 6 and 17 years old. The fall in death rates does not
appear to reflect a change in age at listing or other demo-
graphic characteristics of the candidates over the decade,
as these factors have remained relatively constant. There
has been a similar fall in waiting list death rates in all re-
gions with active intestine transplant programs. Despite
the aforementioned differences in time to transplant be-
tween regions, the annual death rates do not appear to
vary greatly. As previously noted, the median TT has fallen
and this may have contributed to the improvements in wait-
ing list mortality rates. Additionally, there has been a sub-
stantial emphasis in many intestine transplant programs on
intestinal care and rehabilitation for their patients (4,5) and
the falling death rates may reflect improved pretransplant
medical care.
Additional organs listed over time
Intestinal transplant candidates are dependent on par-
enteral nutrition (PN) for survival and the primary indica-
tion for intestinal transplantation is failure of PN therapy
due to the development of life-threatening PN-associated
complications, most commonly PN associated liver dis-
ease. Consequently, most intestinal transplant candidates
are also listed for additional organs, most commonly liver
and/or pancreas. The decision to proceed with a liver list-
ing is usually prompted by a clinical determination that
irreversible liver damage has occurred and that survival is
only possible by including a liver graft at transplant. Con-
versely, while an additional pancreas listing is sometimes
needed for irreversible pancreas disease, more often it is
done to facilitate a multiorgan transplant that is technically
easier when the intimate anatomical relationships of the
liver, pancreas and intestine are preserved. In the interest
of optimal organ utilization, it is important to review and
monitor the use of additional organs in intestinal transplant
candidates.
For this analysis of the timing of the listing of intestine
candidates with additional organs, we limited our sample
to candidates listing for their first intestine transplant and
included listings through 2007 to allow for observation of
listing behavior for 1 year following the intestine listing
(n = 1882 registrations for 1741 individuals). Most of the
124 people with more than one registration were listed
simultaneously at two centers (n = 95), while 13 listed
at three centers, and two listed at four centers. Fourteen
candidates were listed consecutively rather than concur-
rently. Each candidate’s intestine waiting list experience
was consolidated into one record per person. In cases
where candidates listed for intestine concurrently at two
different centers, the listing for the center that eventually
performed the transplant was chosen for those that were
transplanted, and the center with the earliest listing date
was chosen for those who died while waiting. The 14 can-
didates listed consecutively had been removed from the
intestine list for reasons like condition improved, condi-
tion declined and removed in error and were re-listed at
the same program within 15 days. These listings were col-
lapsed into one continuous listing. The final sample tracked
1741 candidates, matched to the waiting lists for other or-
gans at their center to determine listing dates relative to
the intestine listing.
Between 1999 and 2007, 38% of candidates who were
listed for their first intestine transplants were initially listed
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Figure 4: (A) Initial listing of candidates for intestine and other
organs on the same day, 1999–2008. (B) Additional listing of
candidates for intestine transplant after intestine listing date,
1999–2008.
for intestine only, 4% were initially listed for intestine-
pancreas on the same day, 40% were initially listed for
intestine-liver on the same day and 13% were initially
listed for intestine-liver-pancreas. An additional 2% of in-
testine candidates had been listed first for a liver transplant
before subsequently being listed for intestine also. While
most pediatric candidates were initially listed for intestine-
liver transplants (53%), most adult candidates were initially
listed for intestine only (51%). The percentages of initial
listings for intestine only and intestine with liver have re-
mained relatively stable over the past 10 years (Figure 4A).
While Figure 4A displays the additional organs for which
intestine candidates were listed prior to or at the same
time as the intestine listing, intestine candidates are often
listed for additional organs after being added to the intes-
tine waiting list. For the years 1999 to 2007 combined,
34% of all intestine candidates (waiting for their first trans-
plant) were listed for at least one additional organ after
their initial intestine listing (Figure 4B). Overall, the most
common additional organ that intestine candidates were
subsequently listed for was the pancreas (20%), followed
by the liver (10%), and the kidney (4%). With adults (18
years and older), 58% of candidates that were initially listed
for both intestine and liver were subsequently listed for
an additional organ, most commonly pancreas. With pedi-
atric patients, 32% of candidates initially listed for intestine
only and 36% initially listed for intestine-pancreas were
subsequently listed for livers also. Furthermore, 27% of
pediatric patients initially listed for both intestine and liver
were subsequently listed for pancreas. Of note in 2007,
the percentage of patients that had no additional listings
did increase to over 70% for the first time in several years,
as more candidates were listed for liver, intestine and pan-
creas on the same day. Over the span of 1999 to 2007
as a whole, two-thirds of intestine candidates waiting for
their first transplant were either initially or eventually listed
for a liver, which was fairly constant across the years, with
a high of 73% in 1999 and a low of 63% in 2001. Thirty-
eight percent of intestine candidates were either initially
or eventually listed for a pancreas, though this fraction has
increased over time, likely due to OPTN attention ensur-
ing that patients getting a pancreas with their intestine (to
facilitate procurement and implantation of the combined
graft by avoiding unnecessary dissection) are listed on the
pancreas waiting list. The fraction also listed for pancreas
at any time while on the intestine list was 18% in 1999
and 2000, and rose to 55% by 2007. About 5% of intes-
tine candidates (first transplant) were eventually listed for
a kidney during this time period, ranging from 3% to 5%
for most years, although 2006 had 9% and 2007 had 6%.
Evolution of intestine allocation policy
Allocation policy for candidates awaiting intestine only
transplantation has not been changed in the past 10 years;
candidates receive offers for intestines according to their
status on the waiting list. A patient can be listed as urgent
(Status 1), nonurgent (Status 2), or inactive (Status 7). The
criteria for listing in either of the active status categories
are rather broad, and it is not known how consistently they
are applied.
In contrast to the allocation of intestine only grafts, sev-
eral changes in policy have been made in recent years
regarding allocation of a composite liver and intestine al-
lograft. Candidates requiring a simultaneous liver and in-
testine (and possibly other abdominal organ) transplant are
listed on both the intestine waiting list as Status 1 and on
the liver list. Prior to February 2002, the liver candidates
were prioritized according to criteria derived from Child–
Pugh–Turcott scores, into Status 1, 2 (and 2b), or 3. The
procuring Organ Procurement Organization (OPO), at its
own discretion, could offer the liver from a potential liver
and intestine donor to the candidate matched according to
the liver waiting list (which likely would have been a liver
only candidate) or the intestine list could be run, in which
case the composite graft would have been allocated to the
next appropriate patient on the intestine waiting list. There
are little data regarding practices and the determinants of
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which waiting list was run for any given donor, though
proximity to an intestinal transplant program is believed to
frequently have been one factor. There was dissatisfaction
on all sides of this issue. Livers that might have been allo-
cated to a very sick local liver candidate could instead be ex-
ported for a distant liver bowel candidate, while there were
data demonstrating that liver-intestine candidates were at
a substantial competitive disadvantage compared to the
liver only candidates, as manifested by significantly higher
waiting list mortality rates.
In February 2002, the fundamental basis of liver allocation
changed to one based on 90 day waiting list mortality risk
with the introduction of the MELD score for adults and
the PELD for children (6,7). These scores were applied
both to patients listed for liver only, as well as combined
liver and intestine transplant candidates despite the fact
that the latter patients had been excluded from the anal-
yses that were used to validate these measures. While
there was no change in the priority of allocating a com-
posite organ from the intestine list, it did seem likely that
these changes in liver allocation had further focused the
allocation of such grafts to the liver list, and thereby by-
passing the liver-intestine candidates. It also rapidly be-
came clear that the liver-intestine candidates, despite hav-
ing very high pretransplant mortality, were not scoring as
highly on MELD or PELD and therefore not having access
to available donors. The OPTN Liver and Intestine commit-
tee asked the SRTR to confirm and quantify the increased
waiting list mortality risk for candidates awaiting both liver
and intestine transplant in relation to liver only candidates,
as well as to determine if MELD and PELD could still be
expected to predict changes in mortality risk for the liver-
intestine transplant candidates.
The first analysis presented to the OPTN Liver and Intes-
tine Committee in November 2002 demonstrated that the
overall death rate while on the liver transplant waiting list
was eight times higher for candidates awaiting combined
liver and intestine allografts compared to those waiting for
a liver alone. On the basis of a left-truncated Cox model
(censored at the earliest of transplantation, removal from
waiting list, or at 90 days), it was determined that each
one point PELD increase equated to an 11% average in-
crease in mortality on the waiting list for both liver only and
combined liver and intestine candidates, but at any given
PELD score the liver and intestine candidates had a 3.6
times greater risk of mortality at 90 days. This analysis re-
sulted in a change in OPTN policy to give additional MELD
or PELD points to candidates simultaneously listed on the
liver and intestine waiting lists, equating to an additional
waiting list mortality of 10% (8).
These analyses were repeated with a greater amount of
accumulated data in 2006 and a greater discrepancy was
noted in waiting list mortality risks between these two
groups of candidates. Again, there was no evidence of an
interaction between the PELD or MELD scores for liver-
intestine and liver alone candidates in the pediatric age
range (0–17 years), indicating that the difference in wait-
ing list mortality for the two groups stayed the same for all
MELD or PELD scores; in this analysis the mean difference
in mortality risk equated to a difference of 23 PELD points.
For adults, however, there was a large difference in mortal-
ity risk for those with relatively low MELD scores (the liver-
intestine candidates having a significantly higher 3 month
mortality risk). However, as the MELD scores increased,
the waiting list mortality risk for both liver-intestine and liver
only candidates approached similar levels. For this reason,
it was decided to add the additional 23 points to all pedi-
atric PELD or MELD scores automatically and to continue
to add the 10% equivalent risk to adults, which results in
fewer additional points being added as the MELD score
increases.
The OPTN Board of Directors approved this change in De-
cember 2006, along with two other changes meant to fur-
ther refine the allocation process. The first was to clarify
whether a combined liver and intestine allograft could be
allocated to a candidate on the basis of their position on the
intestine list or whether the liver list had to be used. It was
decided that, provided there were no Status 1A or 1B can-
didates in the donor OPTN region to whom the liver could
be offered, the composite liver and intestine allograft could
be offered for a liver-intestine candidate either regionally or
nationally. The second change approved was to offer com-
posite liver-intestine allografts from donors less than 11
years specifically to the candidates listed for both organs,
both regionally and nationally, ahead of candidates listed
regionally for liver only, with the exception of Status 1 liver
alone candidates listed locally or regionally. This change
was made to better serve the pediatric waiting list.
In the same time frame, the tightening of criteria for a
child to be listed as Status 1B that was introduced with the
review of all Status 1 listings made it more difficult for chil-
dren with chronic liver disease to have their listing priority
elevated to this status. One of the criteria made more strin-
gent was the transfusion requirement following gastroin-
testinal (GI) bleeding. It became clear that patients with
GI bleeding awaiting combined liver and intestine trans-
plantation could spend weeks with continuous blood loss
but never achieve the required 30 cc/kg/24 h required to
be upgraded to Status 1B. In May 2007 the transfusion
requirement was reduced back to 10 cc/kg in a 24 h pe-
riod for those candidates listed simultaneously for liver and
intestine.
The most recent change to allocation affecting intestine
and liver candidates is presently being programmed into
UNET and came about as a result of a directive given
to the OPTN Pediatric committee to reduce waiting list
deaths. It was recognized that livers from donors younger
than 11 years of age rarely if ever were used in adults and
consequently these organs could be allocated on a wider
geographical basis to children without adversely affecting
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Table 2: Intestine consent, recovery and transplant by OPTN region, 1999–2008
OPTN region
U.S.
total 1 2 3 4 5 6 7 8 9 10 11
Total deceased donors of at
least 1 organ (N)
69 374 2431 8832 11 257 6396 9581 2561 6237 4548 3833 6433 7265
Disposition of intestine (%)
Consent for IN not requested 18.1 22.0 21.4 18.1 13.7 5.2 10.6 19.1 18.2 28.3 14.1 33.7
Consent for IN not obtained 8.9 12.8 10.0 8.5 8.4 10.2 5.3 5.4 3.5 12.2 11.1 9.6
IN not recovered 69.2 63.4 65.0 67.9 75.9 82.6 82.9 67.0 73.3 56.8 71.4 53.4
IN recovered but not for
transplant
1.7 0.0 1.7 2.5 0.2 0.6 0.2 7.0 2.7 0.3 0.9 0.6
IN recovered for transplant,
discarded
0.2 0 0.2 0.1 0.2 0.1 0.1 0.3 0.1 0.3 0.3 0.2
IN transplanted 1.9 1.8 1.7 3.0 1.5 1.2 0.8 1.2 2.2 2.2 2.2 2.6
Disposition of intestine (N)
Consent for IN not requested 12 571 536 1890 2038 878 499 271 1192 828 1084 907 2448
Consent for IN not obtained 6176 310 883 952 540 981 137 336 159 467 717 694
IN not recovered 47 981 1541 5740 7639 4855 7916 2123 4181 3334 2179 4591 3882
IN recovered but not for
transplant
1174 1 151 278 11 60 6 434 124 10 57 42
IN recovered for transplant,
discarded
125 0 18 15 14 10 3 18 5 10 20 12
IN transplanted 1347 43 150 335 98 115 21 76 98 83 141 187
Source: SRTR analysis, data as of May 2009. IN = intestine.
the adult waiting list. One part of the changes will be to
allocate the young pediatric donor livers to Status 1A pedi-
atric recipients regionally and then nationally before offer-
ing to the combined liver-intestine candidates. This is ex-
pected to reduce the national allocation of composite liver-
intestine allografts by a small but, as of yet, unquantifiable
proportion.
As allocation policy continues to be refined, there is grow-
ing interest in considering the potential to evaluate trans-
plant benefit as a part of allocation strategy (9). Simply
stated, transplant benefit seeks to determine the bene-
fit received with a transplant compared to the benefit re-
ceived without transplantation. Indeed, such consideration
of ‘benefit’ is a foundation of all clinical decision-making.
With respect to survival benefit, this can be determined
by comparing survival with a transplant to survival without
a transplant. Accordingly, to calculate transplant benefit,
one needs statistical models to predict survival both on the
waiting list as well as posttransplant. While this is possible
for many patients considered for liver transplantation, there
are several populations where this approach is less sound,
including liver-intestine candidates. One reason is that the
relatively small number of liver-intestine candidates limits
the statistical power of the survival models. Additionally, all
models use current data to predict future outcomes. Given
the significant improvement in results over recent years in
intestine transplantation, it would be desirable to have the
parameters used in the model be in a relatively steady
state. Any future changes in liver allocation, whether ben-
efit based or not, need to be developed with consideration
of the impact on this unique population.
Donor Utilization
As with all deceased organ donors over the past 10 years,
the number of deceased intestine donors has plateaued
or slightly decreased in the past 3 years. In 2008, there
were 197 intestine donors compared to a peak of 206 in
2007 [Table 1.1]. As detailed previously, the limited number
of intestine donors, coupled with an increase in overall
waiting list registrations, has kept the waiting list mortality
for a patient awaiting an intestine transplant high.
From 1999 to 2008, between 1.2% and 2.4% of deceased
donors of at least one organ were utilized for intestine
donation annually. Of the 69 374 deceased donors be-
tween 1999 and 2008, consent for the intestine was not
requested for 18% and in another 9% of cases, consent
was not granted (Table 2). Failure to request consent for in-
testine transplant varied across OPTN regions during this
time frame from 5% to 34%. Reasons most commonly
stated for not requesting intestine consent were: donor
age (67%), donor was DCD (donation after cardiac death;
11%) and donor quality (8%). Primary reasons listed for the
intestine not being recovered after consent was obtained
include poor organ function (25%), no recipient located
(21%), donor medical history (10%) and organ refused by
all national programs (9%). Not recovering the intestine be-
cause the organ was refused by all national programs has
been increasing over the past 10 years from 1% in 1999
to 16% in 2008.
Efforts to increase the donor pool and improve intestine
waiting list mortality potentially include consideration of
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living intestine donation, DCD donors, extension of accept-
able donor criteria, improved utilization of existing donors,
and optimized donor allocation. Intestine transplants from
living donors have not substantially impacted the intestine
waiting list. After a peak of 13 intestine living donors be-
tween 2004 and 2005, there were only 5 reported between
2006 and 2007, and none in 2008 [Table 1.1]. Similarly, DCD
intestine donation is not expected to significantly impact
intestine availability in the near future, due to the sensitivity
of the intestine to ischemia.
While the intestine waiting list has grown over time, only
212 patients were waiting for intestine transplant at the
end of 2008 [Table 10.1a,b]. Increasing use of existing
donors would be hypothesized to significantly increase in-
testine availability, further reducing waiting list mortality
and time to transplant. In an effort to understand intestine
recovery practice and identify areas for potential improve-
ment, an analysis of the OPTN data during the past 10
years was evaluated for potentially underutilized donors,
using the following criteria for potential intestine donation:
donors 50 years of age or less, who had other organs
utilized (for donors age 0–2 years, any organ used; for
donors age 2–50 years, liver transplanted); terminal AST
and ALT <500; last serum sodium prior to procurement <
170 meq/L; serum creatinine less than 1.0 mg/dL for age
< 1 year or less than 2.0 mg/dL for age > 1 year; con-
firmed negative virus serology (human immunodeficiency
virus [HIV], human T-lymphotropic virus [HTLV], hepatitis B
core antibodies [HBcAb], hepatitis B surface antigen [HB-
sAg] and hepatitis C antibodies [HCV]); two inotropes or
less at time of recovery; if a cardiac arrest occurred after
declaration of brain death and the resuscitation time was
less than 15 min (cardiac arrest <15 min); and donation
after brain death.
Table 3 shows the impact of these criteria, implemented
as exclusions for not meeting the criterion (for exam-
ple, the donor age < 50 years is shown as excluding
all donors older than 50 years), starting with all donors
and ending with the potential intestine donors. In 2008,
approximately 35% of the nearly 8000 deceased donors
of at least one organ met the designated criteria as po-
tential intestine donors. Proportionally, the greatest num-
ber of donors were excluded based on age >50 years,
not having the liver transplanted for donors older than 2
years, evidence of renal insufficiency and cardiac arrest
>15 min.
The actual disposition of the intestine in the potential intes-
tine donors is listed in Table 4. Of note, the rates of ‘con-
sent for intestine not requested’ have fallen in this selected
population from 12% in 1999 to 4% in 2008 and rates of
‘consent for intestine not obtained’ have also fallen. How-
ever, the rates for intestine not recovered have risen to
86% in 2008 from 71% in 1999. Less than 6% (n = 158)
of donors meeting the criteria, listed previously, for poten-
tial intestine donors were transplanted in 2008.
To validate the selection criteria used, the potential intes-
tine donor criteria were applied to actual donors whose
intestine was transplanted during the study period (1999
to 2008). As shown in Table 5, 85% of actual donors utilized
in 2008 met the selection criteria used to search for poten-
tially underutilized intestine donors. Twenty-seven actual
intestine donors (15%) failed to meet at least one criterion
used to define potential intestine donors, most commonly
the serum creatinine criterion (n = 8), cardiac arrest >15
min (n = 9) or more than two inotropes at cross clamp
(n = 4). These data suggest that intestine donor selection
criteria used for this analysis are similar to those used in
current clinical practice, and that intestine donor utilization
may be significantly increased by improvement in obtain-
ing consent, awareness of appropriate age and medical
criteria, as well as standardization of practice across OPTN
regions.
Patient and Graft Survival, Early versus Late
Early patient and graft survival after intestinal transplan-
tation have markedly improved over the past 10 years.
In 1998, the 1-year adjusted graft and patient survival
was 52% and 69%, respectively, while in 2007, these
same survivals increased to 75% and 79%, respectively,
a gain of more than 20 percentage points for graft survival
[Tables 1.11a and 1.12a]. These outcomes are now nearly
on par with other solid organ transplants such as pancreas,
lung and liver. While we cannot determine the reasons
behind this improvement, a multifactorial etiology is pre-
sumed. Important contributing factors include advances in
immunosuppression, increased experience and advances
in the detection and treatment of rejection.
Intestinal transplant recipients have received a variety
of immunosuppressive regimens. Similar to other organ
transplants, there can be a broad range of drug combina-
tions used with the cornerstone for maintenance immuno-
suppression being tacrolimus (Prograf, Astellas, Tokyo,
Japan). A review of the literature suggests that two broad
classes of immunomodulatory agents have gained increas-
ing acceptance and have been associated with marked
improvements in 1-year survival. Antilymphocyte antibody
therapies in the form of rabbit antithymocyte globulin
(rATG, Thymoglobulin, Genzyme Corp., Cambridge, MA)
and alemtuzumab (Campath-1H, Genzyme Corp., Cam-
bridge, MA) have both been reported in single center pub-
lications to be associated with improved short-term sur-
vival and decreased rejection rates and severity (10–12).
Likewise, induction with interleukin-2 receptor antagonists
(daclizumab [Zenapax, Roche Group, Nutley, NJ)] or basilix-
imab [Simulect, Novartis, Basel, Switzerland]) has been as-
sociated with similar improvements in survival and reduc-
tion in acute rejection episodes and their severity (13,14).
OPTN data show that at the time of discharge in 2008,
99% of intestinal transplant recipients received tacrolimus
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Table 3: Assessment of potential intestine donors among donors of at least 1 organ, 1999–2008
Total 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total deceased donors of at least
1 organ (N)
69 373 5824 5986 6080 6190 6457 7152 7594 8019 8087 7984
Potential intestine donors (N) 27 144 1800 2613 2634 2819 2770 2923 2947 2963 2919 2756
Exclusion criteria implemented in
the order listed below (N)
Age>50 years 22 229 1714 1780 1792 1818 2047 2329 2607 2680 2718 2744
Age<2 and no organs
transplanted
36 2 7 2 2 5 5 5 2 3 3
Age≥ 2 and liver not transplanted 8353 804 842 818 752 659 764 818 874 999 1023
Terminal SGOT/AST > 500 u/L 706 48 46 42 56 64 80 80 89 96 105
Terminal SGPT/ALT > 500 u/L 267 14 16 18 18 24 24 30 39 41 43
Last serum sodium > 170 mEq/L 159 0 0 0 0 1 16 40 42 32 28
Serum creatinine>1 mg/dL,
under age 1
135 10 6 9 14 16 17 13 8 23 19
Serum creatinine>2 mg/dL, age
1–50
3637 257 240 286 258 356 348 378 483 505 526
HIV or HTLV not confirmed
negative
146 27 11 7 21 15 7 16 26 10 6
HBV core antibody not negative 1431 146 166 172 125 145 130 136 150 123 138
HBV surface antigen not negative 123 9 8 24 12 9 18 12 14 8 9
HCV antibody not negative 694 54 48 46 59 61 89 76 96 85 80
More than 2 inotropes at cross
clamp
828 14 64 68 78 87 120 98 105 107 87
Did not meet cardiac arrest <15
min
2832 913 115 120 110 136 172 182 257 410 417
Donation after cardiac death 653 12 24 42 48 62 110 156 191 8 0
Potential intestine donors (%) 39.1 30.9 43.7 43.3 45.5 42.9 40.9 38.8 36.9 36.1 34.5
Exclusion criteria implemented in
the order listed below (%)
Age>50 years 32.0 29.4 29.7 29.5 29.4 31.7 32.6 34.3 33.4 33.6 34.4
Age<2 and no organs
transplanted
0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0
Age≥ 2 and liver not transplanted 12.0 13.8 14.1 13.5 12.1 10.2 10.7 10.8 10.9 12.4 12.8
Terminal SGOT/AST > 500 u/L 1.0 0.8 0.8 0.7 0.9 1.0 1.1 1.1 1.1 1.2 1.3
Terminal SGPT/ALT > 500 u/L 0.4 0.2 0.3 0.3 0.3 0.4 0.3 0.4 0.5 0.5 0.5
Last serum sodium > 170 mEq/L 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.5 0.4 0.4
Serum creatinine>1 mg/dL,
under age 1
0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.3 0.2
Serum creatinine>2 mg/dL, age
1–50
5.2 4.4 4.0 4.7 4.2 5.5 4.9 5.0 6.0 6.2 6.6
HIV or HTLV not confirmed
negative
0.2 0.5 0.2 0.1 0.3 0.2 0.1 0.2 0.3 0.1 0.1
HBV core antibody not negative 2.1 2.5 2.8 2.8 2.0 2.2 1.8 1.8 1.9 1.5 1.7
HBV surface antigen not negative 0.2 0.2 0.1 0.4 0.2 0.1 0.3 0.2 0.2 0.1 0.1
HCV antibody not negative 1.0 0.9 0.8 0.8 1.0 0.9 1.2 1.0 1.2 1.1 1.0
More than two inotropes at cross
clamp
1.2 0.2 1.1 1.1 1.3 1.3 1.7 1.3 1.3 1.3 1.1
Did not meet cardiac arrest <15
min
4.1 15.7 1.9 2.0 1.8 2.1 2.4 2.4 3.2 5.1 5.2
Donation after cardiac death 0.9 0.2 0.4 0.7 0.8 1.0 1.5 2.1 2.4 0.1 –
Source: SRTR analysis, data as of May 2009.
for maintenance immunosuppression [Table 10.6e].
During the first posttransplant year, very few patients were
removed from this drug, with nearly 97% remaining on
it [Table 10.6g]. Induction therapy was used in 60% of
recipients [Table 10.6a]. The most commonly used drug
for induction was rATG, with approximately a third of the
patients with induction therapy receiving rATG. Interest-
ingly, 15% of patients were administered muromonab-CD3
(OKT3, Orthoclone OKT3, Centocor Ortho Biotech, Hor-
sham, PA) for induction. Other drugs commonly used for
induction included daclizumab and alemtuzumab. Over the
past four years, a review of immunosuppression use by
discharge regimens demonstrates a wide variety of drug
combinations. No specific trends or changes can be noted
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Table 4: Final disposition of intestine for potential intestine donors identified by selection criteria, 1999–2008
Total 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total potential intestine donors (N) 27 144 1800 2613 2634 2819 2770 2923 2947 2963 2919 2756
Disposition of intestine (%)
Consent for IN not requested 10.3 12.2 14.5 13.5 15.0 12.2 12.4 9.8 6.4 4.3 3.8
Consent for IN not obtained 7.9 12.2 10.8 10.3 8.5 9.0 7.5 6.3 6.5 5.9 3.6
IN not recovered 75.5 71.2 70.5 70.7 70.8 72.5 71.8 76.8 79.6 82.0 86.2
IN recovered but not for transplant 2.0 1.8 1.5 1.9 2.3 2.6 3.6 1.7 2.1 2.0 0.3
IN recovered for transplant, discarded 0.3 0.3 0.1 0.1 0.2 0.2 0.5 0.3 0.3 0.2 0.3
IN transplanted 4.2 2.3 2.6 3.5 3.1 3.5 4.2 5.1 4.9 5.7 5.7
Disposition of Intestine (N)
Consent for IN not requested 2785 219 378 356 422 339 362 289 191 125 104
Consent for IN not obtained 2133 219 283 271 241 249 218 186 194 172 100
IN not recovered 20 483 1281 1842 1862 1997 2009 2100 2263 2359 2393 2377
IN recovered but not for transplant 544 33 39 51 66 71 104 50 63 59 8
IN recovered for transplant, discarded 72 6 3 3 5 6 15 10 10 5 9
IN transplanted 1127 42 68 91 88 96 124 149 146 165 158
Source: SRTR analysis, data as of May 2009.
Notes: selection criteria are delineated in Table 3.
for the years 2004 to 2008. Some of the more common
regimens include alemtuzumab, rATG, or daclizumab, com-
bined with tacrolimus. Interestingly, the use of steroids at
the time of discharge for the years 2004 to 2008 combined
was seen in 75% of the patients, increasing to 83% at 1
year posttranplant [Table 10.6c,g].
Experience is another contributing factor to the early im-
proved outcomes in these highly complex patients. This
factor was first identified through the analyses of the In-
testinal Transplant Registry, an international dataset that
includes nearly all such transplants performed worldwide
to date, where centers performing more than 10 intestinal
transplants had better patient survival than those perform-
ing less than 10 (15). In the United States today, there are
five transplant centers that each have performed 100 or
more intestinal transplants and have contributed heavily to
these results.
Lastly, rejection has been one of the most formidable ob-
stacles to successful intestinal transplantation. These data
demonstrate that rates of rejection treated with antirejec-
tion medication between 2005 and 2008 have been steady
at 30%-40% [Table 10.6i]. In other published literature,
the incidence of rejection after intestinal transplantation
has decreased from historic levels of 80% or more to cur-
rent levels of 20%-40%, mainly related to induction im-
munotherapy. Perhaps even more important is the obser-
vation that the severity of rejection has decreased over
time, coincident with the use of induction agents (16).
Table 5: Characteristics of actual intestine donors (intestine was transplanted), 1999–2008
Total 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total donors with intestine transplanted (N) 1347 71 79 112 106 112 144 170 171 197 185
Meets potential intestine donor criteria (N) 1127 42 68 91 88 96 124 149 146 165 158
Criteria implemented in the order listed below (N)
Age>50 years 10 0 0 3 3 0 1 1 1 1 0
Age<2 and no organs transplanted 6 0 1 0 1 0 1 1 0 1 1
Age≥ 2 and liver not transplanted 14 2 1 0 3 1 3 1 0 0 3
Terminal SGOT/AST > 500 u/L 9 1 0 1 1 0 0 3 2 0 1
Terminal SGPT/ALT > 500 u/L 5 1 1 0 1 1 0 0 0 0 1
Last serum sodium > 170 mEq/L 8 0 0 0 0 0 0 2 4 2 0
Serum creatinine>1 mg/dL, under age 1 30 1 1 1 4 3 4 4 3 4 5
Serum creatinine>2 mg/dL, age 1–50 19 0 0 4 0 2 0 2 4 4 3
HIV or HTLV not confirmed negative 3 0 0 0 1 0 1 0 0 1 0
HBV core antibody not negative 23 5 5 5 1 2 2 1 1 1 0
HBV surface antigen not negative 2 0 0 1 0 0 1 0 0 0 0
HCV antibody not negative 0 0 0 0 0 0 0 0 0 0 0
More than 2 inotropes at cross clamp 23 0 1 3 0 2 1 1 2 9 4
Did not meet cardiac arrest <15 min 68 19 1 3 3 5 6 5 8 9 9
Donation after cardiac death 0 0 0 0 0 0 0 0 0 0 0
Meets potential intestine donor criteria (%) 83.7 59.2 86.1 81.3 83.0 85.7 86.1 87.6 85.4 83.8 85.4
Source: SRTR analysis, data as of May 2009.
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Source: SRTR Analysis, Data as of May 2009.  Isolated Intestine:intestine transplant with no other organs.
Intestine with Liver: includes all transplants with intestine and liver, with or without pancreas or kidney.
Figure 5: Unadjusted patient and graft survival for isolated
intestine and intestine with liver recipients.
Some potentially important evolving advances in the early
detection of rejection include monitoring with serum cit-
rulline (16) and stool calprotectin (17).
Unfortunately, while marked advances in short-term sur-
vival have been seen, long-term survival still remains low
(Figure 5). The 10-year patient survival for isolated intes-
tine and intestine with liver grafts is only 46% and 42%,
respectively. Similarly, the intestine graft survival for the
same interval is only 29% and 39%, respectively. These
outcomes are similar to those seen in lung and heart-lung
transplantation (and graft survival for pancreas) but com-
pare unfavorably to kidney, liver and heart transplantation
where 10-year patient and graft survivals are typically more
than 50%.
The reasons for these results are more difficult to ascer-
tain. Most importantly, these figures are derived from pa-
tients transplanted more than 10 years ago and thus in
the 1990s and earlier. Most in the field of intestinal trans-
plantation would agree that the era of transplantation is
an important determinant of outcome. Therefore, insuffi-
cient time has passed to assess long-term outcomes in the
current era of transplantation. Of concern in these results
is the potential for graft loss due to chronic rejection. In
general, chronic rejection is under-diagnosed and reported
due to limitations in analysis. There are now more pub-
lished reports on chronic rejection after intestinal transplan-
tation (18,19) and the definitive incidence remains to be
seen.
Late Morbidities After Intestinal
Transplantation
Renal function
Short- and long-term renal function after transplantation
of extra-renal solid organs has become a topic of concern
as transplant recipients live longer. The significance of the
problem was exposed in a study by Ojo and colleagues that
examined SRTR data over a 10-year period with a median of
36-months follow-up to determine the incidence of renal
failure (20). The risk of chronic renal failure was highest
in intestinal transplant recipients at 60 months with an
incidence of 21%. Further analysis of intestine transplant
recipients receiving their first transplant who had not been
on dialysis prior to transplant and did not receive a kidney
as part of a multiorgan transplant, between 1999 and 2008,
is shown in Table 6. In interpreting these data, one must
bear in mind that nearly 60% of the recipients are children
and that nonsurvivors are not included. The trend of the
overall data is a 50% increase in serum creatinine from
discharge to 5-year follow-up.
Two single center studies from the University of Miami
examined renal function in pediatric and adult recipients
of intestinal transplants (21,22). By 2 years posttransplant,
both adults and children experienced a significant decrease
in glomerular filtration rate (GFR) which correlated with
tacrolimus levels in the first year posttransplant. In per-
haps the most detailed report to date, the University of
California, Los Angeles examined calculated GFR at mul-
tiple time points after intestinal transplant (23) and com-
pared this value to standard, predicted norms. The results
indicated that, overall, GFR was 84% of normal after in-
testinal transplant and that by 5 years posttransplant, this
value was 64%. Predictors of renal dysfunction included
low pretransplant GFR, ICU-bound prior to transplant and
high-dose tacrolimus therapy. An estimated GFR less than
75% of normal was a predictor of poor survival. These
studies clearly elucidate the scope and gravity of the prob-
lem and that further investigation into preservation of renal
function is of paramount importance.
Posttransplant lymphoproliferative disorder
From the earliest reports, posttransplant lymphoprolifera-
tive disorder (PTLD) has been a major problem in intestinal
transplant recipients, with incidences reported as high as
15%–20% (15,24). Our analysis of patients receiving their
first intestine transplant that didn’t include a kidney, for the
years 1999 to 2008, revealed an unusually low incidence of
PTLD after intestinal transplantation, with incidences rang-
ing from 0.6%–1.3%; inaccurate reporting is a likely expla-
nation. In one of the largest single-center series published
to date, the University of Miami examined PTLD after 119
pediatric intestinal transplants (25). The overall incidence
of PTLD was 11.8% with a median onset 21 months after
transplantation. Fifty percent of cases resulted in graft fail-
ure or death. The administration of OKT3 was the only risk
factor identified. The magnitude of PTLD is significant after
intestinal transplantation and warrants further investigation
into prevention and treatment.
Nutritional status
There are surprisingly few studies examining nutritional
outcomes after intestinal transplantation (26–29). All
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Table 6: Serum creatinine at discharge, 6 months, 1, 3 and 5 years following intestine transplant by year of transplant, 1999–2008
Total 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total deceased donor intestine transplants 1177 57 71 103 91 103 143 150 146 157 156
Discharge∗
Sample size for serum creatinine 1158 57 70 98 88 103 140 149 143 156 154
Mean serum creatinine (mg/dL) 0.65 0.75 0.60 0.66 0.66 0.60 0.62 0.68 0.61 0.71 0.61
Median serum creatinine (mg/dL) 0.50 0.50 0.45 0.60 0.60 0.50 0.50 0.60 0.60 0.60 0.50
Six months posttransplant
Sample size for mean serum creatinine 762 26 45 72 69 86 109 120 107 128 +
Mean serum creatinine (mg/dL) 0.98 1.31 1.13 1.22 0.94 0.86 0.89 0.98 0.90 0.96 +
Median serum creatinine (mg/dL) 0.70 1.25 1.00 0.85 0.70 0.65 0.80 0.80 0.60 0.60 +
One year posttransplant
Sample size for mean serum creatinine 720 29 47 64 66 80 107 110 100 117 +
Mean serum creatinine (mg/dL) 0.99 1.04 1.06 1.05 0.95 0.95 0.95 1.07 1.00 0.91 +
Median serum creatinine (mg/dL) 0.70 0.70 0.90 0.80 0.70 0.60 0.70 0.85 0.85 0.60 +
Three years posttransplant
Sample size for mean serum creatinine 385 21 38 45 49 58 88 86 + + +
Mean serum creatinine (mg/dL) 0.94 1.10 1.11 1.00 0.81 0.87 0.97 0.88 + + +
Median serum creatinine (mg/dL) 0.70 1.00 0.95 0.60 0.70 0.70 0.80 0.60 + + +
Five years posttranplant
Sample size for mean serum creatinine 172 16 29 39 40 48 + + + + +
Mean serum creatinine (mg/dL) 0.92 1.09 0.88 1.01 0.88 0.83 + + + + +
Median serum creatinine (mg/dL) 0.70 0.70 0.80 0.80 0.80 0.50 + + + + +
Source: SRTR analysis, data as of May 2009.
+ Insufficient follow-up available to present statistics for this year. ∗Includes recipients that died or had graft failure prior to discharge.
Notes: sample excluded recipients with prior transplants of any organ, those who received a kidney with their intestine transplant and
those receiving dialysis treatments prior to transplant.
series report a high rate of enteral nutritional autonomy. In-
terestingly, while serum nutritional parameters normalized
posttransplant, the anthropometric data was mixed. In our
analysis of the OPTN/SRTR data, the only available informa-
tion is the center follow-up report on use of parenteral and
enteral feedings. We restricted the population for this anal-
ysis to first intestine transplants and excluded recipients
who also received kidney grafts or who were on dialysis
at transplant. Table 7 shows the percentage of patients re-
ported to require some form of parenteral nutrition at each
follow-up interval by year of transplant. At discharge, nearly
one-third of patients require PN support. However, by
Table 7: Dependence on parenteral nutrition at discharge, 6 months, 1, 3 and 5 years following intestine transplant by year of transplant,
1999–2008
Total 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total deceased donor intestine transplants 1177 57 71 103 91 103 1143 150 146 157 156
Discharge
Total sample size (N) 996 38 54 84 80 91 122 130 124 133 140
Percent using parenteral nutrition (%) 27.6 21.1 20.4 16.7 20.0 26.4 23.8 29.2 31.5 33.8 36.4
Six months posttransplant
Total sample size (N) 775 27 46 74 72 86 113 122 108 127 +
Percent using parenteral nutrition (%) 13.8 29.6 8.7 12.2 4.2 11.6 13.3 14.8 15.7 18.1 +
One year posttransplant
Total sample size (N) 723 29 50 65 66 79 108 109 100 117 +
Percent using parenteral nutrition (%) 9.0 13.8 8.0 12.3 1.5 2.5 4.6 16.5 11.0 10.3 +
Three years posttransplant
Total sample size (N) 402 23 38 50 52 61 91 87 + + +
Percent using parenteral nutrition (%) 5.2 4.3 2.6 2.0 1.9 3.3 6.6 10.3 + + +
Five years posttranplant
Total sample size (N) 184 18 33 42 42 49 + + + + +
Percent using parenteral nutrition (%) 3.8 5.6 12.1 2.4 2.4 0.0 + + + + +
Source: SRTR analysis, data as of May 2009.
+ Insufficient follow-up available to present statistics for this year.
Notes: sample excluded recipients with prior transplants of any organ, those who received a kidney with their intestine transplant and
those receiving dialysis treatments prior to transplant. Parenteral nutrition (PN) status reported only for those alive with a functioning
graft at the specified follow-up period.
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6–12 months after transplantation, this improves signifi-
cantly. Indeed, at one year, nearly 90% of intestine recipi-
ents are independent of PN support.
Retransplantation outcomes
There have been a limited number of retransplantation pro-
cedures involving the intestine; a total of 131 over the ten
years of this report (1999 to 2008) [Table 10.4]. In 2008,
there were 20 intestine retransplants performed which rep-
resented 11% of all intestine transplants. As more experi-
ence is gained with primary intestinal transplantation, it is
logical that retransplant procedures will also increase. Of
the 131 intestine retransplantation recipients, nearly 50%
were hospitalized at the time of subsequent transplanta-
tion. The primary indications for retransplantation (i.e. the
causes of graft failure for the previous transplant) were
acute and chronic rejection in 31% and 29%, respectively.
While 24% died prior to hospital discharge, 72% were dis-
charged alive with a functioning graft. Of concern, 35%
were discharged home with PN support. In unsuccessful
cases, graft failure and sepsis were reported as the leading
causes of patient death and rejection as the leading cause
of graft loss.
The only single-center report focused on intestinal retrans-
plantation is from the University of Pittsburgh and includes
14 patients with a mean follow-up of 56 months (30). Re-
jection was the most common indication for retransplan-
tation. Excellent patient and graft survival was reported
following retransplant (71% and 55%, respectively). As re-
transplantation of the intestine becomes more common,
more analysis is required to determine suitable candidates
and improve overall outcomes.
Summary
Intestine transplant candidates have noted substantial im-
provements in time to transplant and waiting list mortality
between 1999 and 2008. Areas for further progress include
augmenting donor consent rates and utilization. A mod-
est increase in the current utilization of 2%–3% of organ
donors as intestine donors could significantly impact wait-
ing list mortality or eliminate it altogether. Although the
number of intestine only registrations is stable, the pro-
portion overall receiving multiple allografts suggests that
efforts at earlier referral, consensus on optimal timing for
transplantation and continued efforts at intestine rehabil-
itation are still urgently needed. Short-term results with
intestine transplantation have significantly improved over
the decade but minimizing graft loss from chronic rejec-
tion and optimizing long-term immunosuppression man-
agement may improve long-term patient and graft survival.
Finally, more data on long-term morbidity, nutritional au-
tonomy and quality of life are needed to better determine
the overall benefit that intestine transplantation affords
patients.
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